16.09.2015 Views

Clinical Pharmacology and Therapeutics

A Textbook of Clinical Pharmacology and ... - clinicalevidence

A Textbook of Clinical Pharmacology and ... - clinicalevidence

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

16 PHARMACOKINETICS<br />

begins slowly <strong>and</strong> accelerates as plasma concentration<br />

falls (Figure 3.7).<br />

2. The time required to eliminate 50% of a dose increases<br />

with increasing dose, so half-life is not constant.<br />

3. A modest increase in dose of such a drug disproportionately<br />

increases the amount of drug in the body once the drugelimination<br />

process is saturated (Figure 3.8). This is very<br />

important clinically when using plasma concentrations of,<br />

for example, phenytoin as a guide to dosing.<br />

Key points<br />

• Two-compartment model. Following a bolus dose the<br />

plasma concentration falls bi-exponentially, instead<br />

of a single exponential as in the one-compartment<br />

model. The first () phase mainly represents<br />

distribution; the second () phase mainly represents<br />

elimination.<br />

• Non-linear (‘dose-dependent’) kinetics. If the<br />

elimination process (e.g. drug-metabolizing enzyme)<br />

becomes saturated, the clearance rate falls.<br />

Consequently, increasing the dose causes a<br />

disproportionate increase in plasma concentration.<br />

Drugs which exhibit such properties (e.g. phenytoin)<br />

are often difficult to use in clinical practice.<br />

Case history<br />

A young man develops idiopathic epilepsy <strong>and</strong> treatment<br />

is started with phenytoin, 200 mg daily, given as a single<br />

dose last thing at night. After a week, the patient’s serum<br />

phenytoin concentration is 25 μmol/L. (Therapeutic range is<br />

40–80 μmol/L.) The dose is increased to 300 mg/day. One<br />

week later he is complaining of unsteadiness, there is nystagmus<br />

<strong>and</strong> the serum concentration is 125 μmol/L. The<br />

dose is reduced to 250 mg/day. The patient’s symptoms<br />

slowly improve <strong>and</strong> the serum phenytoin concentration<br />

falls to 60 μmol/L (within the therapeutic range).<br />

Comment<br />

Phenytoin shows dose-dependent kinetics; the serum concentration<br />

at the lower dose was below the therapeutic<br />

range, so the dose was increased. Despite the apparently<br />

modest increase (to 150% of the original dose), the plasma<br />

concentration rose disproportionately, causing symptoms<br />

<strong>and</strong> signs of toxicity (see Chapter 22).<br />

FURTHER READING<br />

Rowl<strong>and</strong> M, Tozer TN. Therapeutic regimens. In: <strong>Clinical</strong> pharmacokinetics:<br />

concepts <strong>and</strong> applications, 3rd edn. Baltimore, MD: Williams<br />

<strong>and</strong> Wilkins, 1995: 53–105.<br />

Birkett DJ. Pharmacokinetics made easy (revised), 2nd edn. Sydney:<br />

McGraw-Hill, 2002. (Lives up to the promise of its title!)

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!